Martinsried / Munich, Germany (Press Release) – Medigene AG (FSE: MDG1, Prime Standard, SDAX), a clin­i­cal stage immuno-oncology com­pany focusing on the devel­op­ment of T cell immuno­therapies, announced today that it has dosed the first patient in its first-in-human clin­i­cal trial with its TCR ther­apy can­di­date MDG1011. The Phase I/II trial in­ves­ti­gates the safety and feasibility of MDG1011 for the treat­ment of various types of blood cancer, in­­clud­ing acute myeloid leukemia (AML), myelo­dys­plastic syn­drome (MDS) and multiple myeloma (MM). MDG1011 is a novel immuno­therapy can­di­date using patient-derived, T cell re­cep­tor (TCR)-modified T cells targeting …